(Source: Gilead Sciences Inc) -- Interim Analyses Results from Study 115 to be Presented as a Late-Breaking Abstract at the American Society of Hematology (ASH) Annual Meeting -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 16, 2015-- Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (NASDAQ:GILD) today announced that its Phase 3 Study 115 evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival...
↧